Major contributions of AARDEX Group to HIV medication adherence monitoring and management

AUG-2018 : Amsterdam, 22nd International AIDS Conference: AARDEX Group presented

AUG-2018 : Amsterdam, 22nd International AIDS Conference: AARDEX Group presented the results of a 5-year successful project on HIV medication adherence management program, confirming the benefits of adherence feedback based on MEMS® technology. 

The implementation of this program in demanding low resource settings was made possible thought a grant from The Bill and Melinda Gates foundation. The HIV prevention program (PrEP) is implemented in various populations at risk for HIV across 3 African countries. It involves 1716 subjects recruited in Kenya (#1421), Senegal (#181) and Nigeria (#114). Download here the ePoster.

Once more, AARDEX Group confirms its leading contribution to monitor and manage HIV medication adherence by deploying its MEMS® technology in more than 70 HIV related projects, involving 20’000+ subjects across 70 countries on all continents.

MEMS, medAmigo and AARDEX are AARDEX Group registered marks.

Share This Post

You may also like...

Breaking News

Is Neglecting Medication Adherence in Neurology Drug Trials Putting Patients at Risk?

The list of Neurological conditions is considerable, with epilepsy, Alzheimer’s disease, dementia, stroke, migraine, multiple sclerosis, Parkinson’s disease, neuro infections, and brain tumors, all attributed to this category of disease. Hundreds of millions of people worldwide are affected by neurological

Bias in clinical Research
Breaking News

Unmasking Bias in Clinical Research: A Historical Perspective

It’s an uncomfortable truth that decision-making is a murky business. While we would all like to think that our actions and the choices underpinning them are rooted in logic, integrity, and reason, the truth is not entirely clear-cut. In reality,